Matinas BioPharma Holdings (MTNB) FCF Payout Ratio (2017 - 2018)

Matinas BioPharma Holdings (MTNB) posted quarterly FCF Payout Ratio of 0.2 for Q3 2018, down 24454.4% quarter-over-quarter from 0.0 in Q2 2018.

Matinas BioPharma Holdings (MTNB) FCF Payout Ratio (2017 - 2018) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has reported FCF Payout Ratio for 2 consecutive years, with 0.2 the latest figure, recorded in Q3 2018.

In Q3 2018, FCF Payout Ratio changed N/A year-over-year to 0.2; the TTM figure through Sep 2018 stood at 0.1 (changed N/A YoY), while the FY2017 annual figure was 0.05, changed N/A from the prior year.
FCF Payout Ratio fell to 0.2 in Q3 2018 per MTNB's latest filing, from 0.0 in the prior quarter.
Across five years, FCF Payout Ratio topped out at 0.05 in Q4 2017 and bottomed at 0.2 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	138.89 Bn	131.04 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.05 Bn	78.06 Bn	3.93 Bn	0.17
3	Argenx Se	65.56 Bn	60.38 Bn	1.37 Bn	-
4	Moderna	55.46 Bn	50.32 Bn	52.00 Mn	-
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	-
7	BioNTech SE	27.70 Bn	9.30 Bn	668.28 Mn	-
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	-
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	0.07
10	Matinas BioPharma Holdings	1.24 Mn	425,394.89	-	-

Download Data